Literature DB >> 33737656

Pterostilbene promotes mitochondrial apoptosis and inhibits proliferation in glioma cells.

Yong Chen1, Haiyan Huang2, Haijun Gao3,4, Ziqiang Liu3, Weidong Xu3, Qunhui Wang3, Chaochao Zhang3, Yaonan Ding3, Weiguang Nie3, Jiacheng Lai3.   

Abstract

Glioma is the most general primary and lethal intracranial malignant tumor. Pterostilbene (PTE), an analog of stilbene and resveratrol, has attracted attention in recent years due to its significant antitumor activity in multiple solid tumors; however, its effect on drug-resistant glioma cells and the underlying mechanism have not yet been reported. In this study, we found that pterostilbene inhibited proliferation, induced intrinsic mitochondria-mediated apoptosis and caused S phase arrest, inhibited migration and excessive invasion in glioma cells. Pretreatment with the pan-caspase-inhibitor Z-VAD-FMK attenuated the PTE-induced apoptosis of glioma cells. Moreover, PTE significantly increased the production of reactive oxygen species (ROS) and reduce the mitochondrial membrane potential (MMP). Inhibition of ROS with N-acetyl-L-cysteine not only rescued PTE-induced reduction of cellular viability but also prevented glioma cell apoptosis. We also discovered ERK 1/2 and JNK signaling pathways were activated by PTE and contributed to induce glioma cell apoptosis. In addition, specific inhibitors of ERK 1/2 and JNK attenuated PTE-induced apoptosis. Besides, PTE significantly reduced tumor volume and prolonged median survival of tumor-bearing rats in vivo. In summary, the results of this study indicate that the anti-tumor effect of PTE on glioma cells may provide a new treatment option for glioma patients.

Entities:  

Year:  2021        PMID: 33737656     DOI: 10.1038/s41598-021-85908-w

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  62 in total

1.  A pterostilbene derivative suppresses osteoclastogenesis by regulating RANKL-mediated NFκB and MAPK signaling in RAW264.7 cells.

Authors:  Kumar Nikhil; Shruti Sharan; Partha Roy
Journal:  Pharmacol Rep       Date:  2015-05-30       Impact factor: 3.024

2.  Synthetic β-nitrostyrene derivative CYT-Rx20 as inhibitor of oral cancer cell proliferation and tumor growth through glutathione suppression and reactive oxygen species induction.

Authors:  Yen-Yun Wang; Yuk-Kwan Chen; Ya-Ling Hsu; Wen-Chin Chiu; Chun-Hao Tsai; Stephen Chu-Sung Hu; Pei-Wen Hsieh; Shyng-Shiou F Yuan
Journal:  Head Neck       Date:  2017-03-27       Impact factor: 3.147

Review 3.  Glioblastoma: pathology, molecular mechanisms and markers.

Authors:  Kenneth Aldape; Gelareh Zadeh; Sheila Mansouri; Guido Reifenberger; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2015-05-06       Impact factor: 17.088

4.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

5.  Resveratrol, pterostilbene, and piceatannol in vaccinium berries.

Authors:  Agnes M Rimando; Wilhelmina Kalt; James B Magee; Jim Dewey; James R Ballington
Journal:  J Agric Food Chem       Date:  2004-07-28       Impact factor: 5.279

6.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

Review 7.  A review of pterostilbene antioxidant activity and disease modification.

Authors:  Denise McCormack; David McFadden
Journal:  Oxid Med Cell Longev       Date:  2013-04-04       Impact factor: 6.543

8.  Biological activity of tumor-treating fields in preclinical glioma models.

Authors:  Manuela Silginer; Michael Weller; Roger Stupp; Patrick Roth
Journal:  Cell Death Dis       Date:  2017-04-20       Impact factor: 8.469

9.  Long Non-coding RNAs Contribute to the Inhibition of Proliferation and EMT by Pterostilbene in Human Breast Cancer.

Authors:  Yongye Huang; Juan Du; Yan Mi; Tianye Li; Ying Gong; Hongsheng Ouyang; Yue Hou
Journal:  Front Oncol       Date:  2018-12-18       Impact factor: 6.244

10.  Pterostilbene Decreases the Antioxidant Defenses of Aggressive Cancer Cells In Vivo: A Physiological Glucocorticoids- and Nrf2-Dependent Mechanism.

Authors:  María Benlloch; Elena Obrador; Soraya L Valles; María L Rodriguez; J Antoni Sirerol; Javier Alcácer; José A Pellicer; Rosario Salvador; Concha Cerdá; Guillermo T Sáez; José M Estrela
Journal:  Antioxid Redox Signal       Date:  2016-03-15       Impact factor: 8.401

View more
  1 in total

1.  GPX8 as a Novel Prognostic Factor and Potential Therapeutic Target in Primary Glioma.

Authors:  Zhao-Shou Yang; Qin Yang; Xiao-Xiao Sun; Kui Xiong; Xiao-Ting Zhu; Yi-Chen Wang; Qian-Yao Ren; Guo-Hui Wu; Shi-Min Wang; Xu-Qin Cao; Xiao-Rong Yang; Wen-Gong Jiang
Journal:  J Immunol Res       Date:  2022-08-23       Impact factor: 4.493

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.